Seagen

Biotechnology

Seagen (acquired by Pfizer in 2023) pioneered antibody-drug conjugates (ADCs) that deliver toxic payloads specifically to cancer cells. The company's ADC technology combines the targeting of antibodies with the killing power of chemotherapy. Seagen's success in hematologic malignancies and solid tumors validated ADCs as a major cancer treatment modality.

The Biology of Business

Sign up to be notified when the book is available to order.

Notify Me